Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $100.30 | Total: $501.50 |
| 1 | 10 | $84.96 | Total: $849.60 |
| 1 | 25 | $71.98 | Total: $1,799.50 |
| 1 | 50 | $61.36 | Total: $3,068.00 |
| 1 | 100 | $53.10 | Total: $5,310.00 |
Overview
AU-15330 is a protein hydrolysis-targeted chimeric (PROTAC) degrader of the SWISNF ATPase subunits SMARCA2 and SMARCA4.AU-15330 potently inhibits tumor growth in a prostate cancer xenograft model and acts synergistically with the AR antagonist enzalutamide.AU-15330 shows partial therapeutic efficacy and non-toxicity with the AR antagonist enzalutamide in a desmoplasia-resistant prostate cancer (CRPC) model. AU-15330 showed partial therapeutic efficacy in a denervation-resistant prostate cancer (CRPC) model and AU-15330 was characterized by non-toxicity.
Chemical Properties
| Molecular Formula | C39H49N9O5S |
| Molecular Weight | 755.93 |
| CAS Numbers | 2380274-50-8 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C[C@H](NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](NC(=O)CN1CCN(CC1)c1cc(nnc1N)-c1ccccc1O)C(C)(C)C)c1ccc(cc1)-c1scnc1C |
Storage and Handling
0C Short Term, -20C Long Term
References
Xiao L, et al. Targeting SWISNF ATPases in enhancer-addicted prostate cancer. Nature. 2022;601[7893] 434-439.